KPTI Karyopharm Therapeutics Inc.

9.62
-0.19  -2%
Previous Close 9.81
Open 9.66
Price To Book 3.41
Market Cap 584009767
Shares 60,707,876
Volume 450,251
Short Ratio
Av. Daily Volume 865,721

SEC filingsSee all SEC filings

  1. 8-K - Current report 181214068
  2. 8-K - Current report 181203159
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170572
  4. 8-K - Current report 181168144
  5. 8-K - Current report 181140254

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data presented at ASH 2016.
Selinexor - SAIL
Acute myeloid leukemia (AML)
Phase 2 initiated April 2014. Interim data at ASCO 2015
Selinexor - (KING study)
Cancer - glioblastoma
Phase 3 top-line data due end of 2019.
Selinexor - SEAL
Dedifferentiated liposarcoma
PDUFA date under priority review April 6, 2019.
Selinexor
Quadruple Refractory Multiple Myeloma
Phase 3 enrollment to be completed 2018 with data due end of 2019.
Selinexor - BOSTON
Multiple myeloma
Phase 2b top-line data at ASH December 1, 2018 - 29.6% ORR Including 9.6% CR.
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 data presented at ASCO 2015. Phase 3 trial to be initiated late 2017.
Selinexor (SIGN Study)
Cancer - Advanced Gynecologic Malignancies (SIGN Study)
Phase 2 trial terminated.
Selinexor - SIRRT
Richter's transformation
Phase 2 trial terminated.
Selinexor - SHIP
Cancer - hormone-refractory prostate cancer (HRPC)
Phase 3 top-line data due 2020.
Selinexor - SIENDO
Endometrial cancer
Phase 2 data due 1H 2019.
Eltanexor
Solid tumors
Phase 1/2 updated tolerability data due 2Q 2019.
KPT-9274
Non-Hodgkin Lymphoma

Latest News

  1. Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  2. Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting
  3. The 4 Healthcare Stocks To Watch On Monday
  4. Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
  5. Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections Moving into 2018
  6. Edited Transcript of KPTI earnings conference call or presentation 8-Nov-18 1:30pm GMT
  7. Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates
  8. Karyopharm Therapeutics: 3Q Earnings Snapshot
  9. Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
  10. Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
  11. Karyopharm to Present at the Jefferies 2018 London Healthcare Conference
  12. Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th
  13. Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting
  14. Is Karyopharm Therapeutics Inc (NASDAQ:KPTI) Potentially Underrated?
  15. Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option
  16. Karyopharm Therapeutics Announces Management Change
  17. Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes
  18. Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes

SEC Filings

  1. 8-K - Current report 181214068
  2. 8-K - Current report 181203159
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170572
  4. 8-K - Current report 181168144
  5. 8-K - Current report 181140254
  6. 8-K - Current report 181124618
  7. 8-K - Current report 181117270
  8. 8-K - Current report 181113774
  9. 8-K - Current report 181112147
  10. 8-K - Current report 181070032